title: [Teriparatide:benefit and safety for bone disease in CKD patients undergoing hemodialysis].
abstract: Teriparatide, 1-34 parathyroid hormone, is one of effective treatments for osteoporosis. Teriparatide shows an anabolic effect for bone formation, as a result, increases bone mineral density as well as prevention of fractures in the general population. On the other hand, there are a few report about the effect of teriparatide on increase of bone mineral density in maintenance hemodialysis patients. In addition to CKD-MBD, osteoporosis is also an important pathological change in ESRD patients, therefore its safety and efficacy should be discussed in more detail.
authors: Blood Purification Center, Niigata University Medical and Dental Hospital, Niigata, Japan.
authors: Suguru
authors: S
authors: Yamamoto
authors: Santo-second clinic, Japan.
authors: Isei
authors: I
authors: Ei
authors: Division of Clinical Nephrology and Rheumatology,Niigata University Graduate School of Medical and Dental Sciences, Japan.
authors: Ichiei
authors: I
authors: Narita
mesh_terms: D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001847:Bone Diseases / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D010281:Parathyroid Hormone / Q000097:blood; D006435:Renal Dialysis; D051436:Renal Insufficiency, Chronic / Q000150:complications*; D019379:Teriparatide / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D050071:Bone Density Conservation Agents; D010281:Parathyroid Hormone; D019379:Teriparatide